Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fitzpatrick

Showing results (461-470 of 717) with videos related to

Pageof 72
Sort By:
Vaccine|September 30, 2023
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022Meagan C Fitzpatrick, Rachel S Laufer, Ranju Baral, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 14, 2023
Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitroAlec T Salminen, Kelly J Davis, Robert P Felton, et al.
Journal of Medicinal Chemistry|August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibitionYong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Regulatory Toxicology and Pharmacology : RTP|May 13, 2019
Exploring current read-across applications and needs among selected U.S. Federal AgenciesGrace Patlewicz, Lucina E Lizarraga, Diego Rua, et al.
Frontiers in Microbiology|July 24, 2024
Phylogenetic and phenotypic characterization of <i>Burkholderia pseudomallei</i> isolates from Ghana reveals a novel sequence type and common phenotypesKevin L Schully, Logan J Voegtly, Gregory K Rice, et al.
PLOS Global Public Health|November 15, 2023
Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trialAhmed M Arzika, Ramatou Maliki, Abdou Amza, et al.
Environment International|December 30, 2024
Private, public, and bottled drinking water: Shared contaminant-mixture exposures and effects challengePaul M Bradley, Kristin M Romanok, Kelly L Smalling, et al.
BMJ Open|August 30, 2023
Antenatal, intrapartum and infant azithromycin to prevent stillbirths and infant deaths: study protocol for SANTE, a 2×2 factorial randomised controlled trial in MaliAmanda J Driscoll, Fadima Cheick Haidara, Milagritos D Tapia, et al.
The American Journal of Tropical Medicine and Hygiene|April 8, 2025
Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1-11 Versus 1-59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in NigerAhmed M Arzika, Ramatou Maliki, Abdou Amza, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 17, 2016
The affordability for patients of a new universal MDR-TB coverage model in ChinaY-Z Ruan, R-Z Li, X-X Wang, et al.
Pageof 72

Showing results (461-470 of 717) with videos related to

Sort By:
Pageof 72
Vaccine|September 30, 2023
Report of the WHO technical consultation on the evaluation of respiratory syncytial virus prevention cost effectiveness in low- and middle-income countries, April 7-8, 2022Meagan C Fitzpatrick, Rachel S Laufer, Ranju Baral, et al.
Toxicology in Vitro : an International Journal Published in Association with BIBRA|June 14, 2023
Parallel evaluation of alternative skin barrier models and excised human skin for dermal absorption studies in vitroAlec T Salminen, Kelly J Davis, Robert P Felton, et al.
Journal of Medicinal Chemistry|August 22, 2003
Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-[1-(4-fluoro-3- morpholin-4-ylphenyl)ethyl]-3- (4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibitionYong-Jin Wu, Carl D Davis, Steven Dworetzky, et al.
Regulatory Toxicology and Pharmacology : RTP|May 13, 2019
Exploring current read-across applications and needs among selected U.S. Federal AgenciesGrace Patlewicz, Lucina E Lizarraga, Diego Rua, et al.
Frontiers in Microbiology|July 24, 2024
Phylogenetic and phenotypic characterization of <i>Burkholderia pseudomallei</i> isolates from Ghana reveals a novel sequence type and common phenotypesKevin L Schully, Logan J Voegtly, Gregory K Rice, et al.
PLOS Global Public Health|November 15, 2023
Comparison of door-to-door and fixed-point delivery of azithromycin distribution for child survival in Niger: A cluster-randomized trialAhmed M Arzika, Ramatou Maliki, Abdou Amza, et al.
Environment International|December 30, 2024
Private, public, and bottled drinking water: Shared contaminant-mixture exposures and effects challengePaul M Bradley, Kristin M Romanok, Kelly L Smalling, et al.
BMJ Open|August 30, 2023
Antenatal, intrapartum and infant azithromycin to prevent stillbirths and infant deaths: study protocol for SANTE, a 2×2 factorial randomised controlled trial in MaliAmanda J Driscoll, Fadima Cheick Haidara, Milagritos D Tapia, et al.
The American Journal of Tropical Medicine and Hygiene|April 8, 2025
Costs, Coverage, and Acceptability of Azithromycin Mass Administration to Children 1-11 Versus 1-59 Months Old to Reduce Mortality: A Cluster-Randomized Trial in NigerAhmed M Arzika, Ramatou Maliki, Abdou Amza, et al.
The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|April 17, 2016
The affordability for patients of a new universal MDR-TB coverage model in ChinaY-Z Ruan, R-Z Li, X-X Wang, et al.
Pageof 72